ArrowMark Colorado Holdings LLC Acquires 80,986 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

ArrowMark Colorado Holdings LLC lifted its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,354,508 shares of the company’s stock after purchasing an additional 80,986 shares during the period. ArrowMark Colorado Holdings LLC owned 1.92% of ORIC Pharmaceuticals worth $13,884,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ORIC. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ORIC Pharmaceuticals by 162.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock worth $36,000 after buying an additional 3,188 shares during the last quarter. Quest Partners LLC raised its stake in shares of ORIC Pharmaceuticals by 253.2% in the 2nd quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock valued at $73,000 after acquiring an additional 7,440 shares in the last quarter. Creative Planning bought a new position in shares of ORIC Pharmaceuticals in the 3rd quarter valued at approximately $116,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in ORIC Pharmaceuticals in the 3rd quarter worth approximately $132,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in ORIC Pharmaceuticals by 71.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock worth $139,000 after purchasing an additional 5,646 shares during the period. 95.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Oppenheimer reduced their price objective on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Wells Fargo & Company began coverage on shares of ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an “overweight” rating and a $20.00 target price for the company. Stifel Nicolaus started coverage on shares of ORIC Pharmaceuticals in a report on Friday, September 6th. They set a “buy” rating and a $20.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Tuesday, November 12th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research report on Monday, November 4th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, ORIC Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $18.29.

ORIC Pharmaceuticals Stock Up 2.7 %

Shares of ORIC opened at $10.17 on Tuesday. The company has a 50-day simple moving average of $9.53 and a 200-day simple moving average of $9.35. ORIC Pharmaceuticals, Inc. has a 52 week low of $6.33 and a 52 week high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.01). On average, research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.84 earnings per share for the current fiscal year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.